Delighted to welcome Prof. Tony Cunningham, a world-renowned viral immunologist and #infectiousdiseases expert, to our clinical advisory board!. His expertise in #shingles and herpes vaccine development will support our Solexan™ pipeline. Read more:

We are thrilled to share our recent collaboration with @fabian_kong to explore the utility of our #antimicrobial formulations against oral gonorrhoea!.

Our antimicrobial #fattyacid technology is showing real promise for the prevention and treatment of a range of #infectiousdiseases. The team, led by Thomas Rau and @_drfosh, has worked extremely hard this year to make this happen. Thank you for all your efforts!.

It was great to share the progress we made in 2022 towards a #shingles #clinicalresearch program at our AGM today:.-Appointed a KOL.-Appointed a CRO.-Appointed a Trial Pathway Partner.-Developed key clinical assets & a clinical pathway plan.-Completed our 1st in-human skin study

Our topical #therapy GS-1 has passed its first human safety test. After repeated skin application in 100 subjects GS-1 ‘did not demonstrate a potential for eliciting dermal irritation or . potential for inducing sensitization’. An exciting milestone for our #shingles program.

We're so excited to see the latest application of our #fattyacid tech online! . Our spin-off company @TenCarbonChem shows that GS-2 is a powerful, broad-spectrum, & safe environmental #antimicrobial. Congratulations to our team members @_drfosh & Tom Rau, & all involved! 👏👏.

A true believer in our cause to provide safe and sustainable antimicrobials to the world, Carolyn is objectives driven, focused, and committed to obtaining the best outcomes for our clients and for the company. We’re so fortunate to have you, Carolyn!. 4/4.

After the acquisition of her company, Carolyn joined us in Q3 2021. Carolyn is capitalising on her experience by optimising our commercial pipelines to bring our best products to market & seeing our @TenCarbonChem customers receive superior products at cost-effective prices. 3/4.

Carolyn has an extensive background in pharmaceuticals and corporate business management. She worked in international biomedical organisations and then translated that experience into running her own private business in the allied healthcare sector. 2/4.

We’re delighted to introduce our superstar Operations Manager, Carolyn Riska. 1/4

Looking for an exciting #PhD project working on novel environmental #antimicrobials?. Our spin-off company TCC is partnering with @ResearchRMIT to support a PhD project to do this. Get the best of both academia and industry - a great way to kickstart your career in science.

Link to the original article published in @IDSAInfo in May 2022👇 .

New Study: Adults age 50+ who had COVID-19 are 15% more likely to develop #Shingles within 6 months. “This pain is significant—it’s excruciating pain—which there is really not a great treatment for.". The Shingles vaccine Shingrix is the best defense.

Tom is also leading the development of this technology for environmental & agricultural applications through our spin-off company Ten Carbon Chemistry. On top of all this, Tom is an all-round great guy to work with. We’re fortunate to be working with you, Tom. 4/4.

Since inventing a novel method for harnessing the antimicrobial power of fatty acids, Tom has been working tirelessly to use this method to develop new & effective therapies for #infectiousdiseases. 3/4.

Tom is the genius behind our technology (although he’s far too humble to ever admit it). With over 20 years of experience in microbiology + a strong interest in creating solutions to #antimicrobialresistance, he’s the perfect person to lead our R&D. 2/4.

We want you to get to know more of our amazing team!. Meet the Co-Founder & Chief Scientific Officer of Wintermute Biomedical, Dr. Tom Rau. #CSO #Founder #Biotech. 1/4

Alyce is also working with our spin-off company Ten Carbon Chemistry overseeing the scientific development of novel antimicrobials for many environmental & agricultural applications. Welcome to the team, Alyce!. 4/4.

Eager to expand her skillset, Alyce is also managing our website & social media accounts as well as supporting the development of investor pitches & research budgets. 3/4.

Alyce obtained her PhD from @LIMSLTU, @latrobe in 2020. Interested in business & translational science, Alyce joined us part-time in Sept 2021. Her main role is to manage & coordinate a Phase IIa Clinical Trial to test the efficacy of GS-1 against #Shingles. 2/4.